Understand the source comparison
LL-37 Half-Life: Research vs Clinical Comparison
Human plasma (in vivo) 90–120 minutes Renal filtration + protease cleavage (elastase, proteinase-3) N/A. Endogenous clearance Short half-life is intentional regulatory mechanism to prevent sustained inflammation Lyophilised powder at −20°C 12–18 months (>95% p
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Human plasma (in vivo)
- 90–120 minutes
- Renal filtration + protease cleavage (elastase, proteinase-3)
- N/A. Endogenous clearance
- Short half-life is intentional regulatory mechanism to prevent sustained inflammation
- Lyophilised powder at −20°C
- 12–18 months (>95% purity retention)
- Minimal. Oxidation blocked by cold + lack of water
- Vacuum-sealed vials, desiccant, <−18°C
- Gold standard for long-term peptide preservation; no procedural shortcuts
- Reconstituted at 4°C (pH 6.0 buffer)
- 21–28 days (>90% activity retention)
- Slow oxidation at methionine residues
- Sterile bacteriostatic water, sealed vial, 2–8°C refrigeration
- Practical maximum for multi-dose protocols; aliquoting recommended after 14 days
- Reconstituted at 4°C (pH 7.4 PBS)
- 10–14 days (>85% activity retention)
- Accelerated hydrolysis + oxidation
- Refrigeration, minimal air exposure
- Common but suboptimal; pH matters more than most protocols acknowledge
- Room temperature (22°C, aqueous)
- 48–72 hours (60–70% activity retention)
- Rapid oxidation + proteolytic contamination risk
- None. Degradation inevitable
- Acceptable only for same-day use; any delay requires immediate refrigeration